New Insights on Dry Eye Disease: Targeting Evaporation (CME Monograph)

To obtain credit for this course after reading this supplement to Ophthalmology Management, click Take Course (above or to the right) and complete the Posttest and Evaluation. A certificate will be instantly available.

Activity Description and Purpose

Dry eye disease (DED) is a common condition associated with significant quality-of-life and economic burdens. The DED pathogenic pathway is triggered by evaporation and the loss of tear film stability. Pharmacotherapy options for managing DED are expanding with the introduction of a new topical agent targeting evaporation and a novel cyclosporine formulation.

Combining didactic material and case-based discussions presented by an expert faculty, this educational activity reviews DED prevalence, risk factors, pathophysiology, diagnosis, and treatment. The desired results of this activity are to cement ophthalmologists’ knowledge of the role of evaporation in the pathogenesis of DED and help them obtain practical strategies for screening, diagnosis, and effective treatment that can improve patient outcomes.

Target Audience

This educational activity is intended for ophthalmologists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Review the function of the tear film in maintaining a healthy ocular surface
  • Use diagnostic strategies to identify dry eye disease in routine practice
  • Identify treatments for a variety of patients with dry eye disease according to clinical evidence
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Course opens: 
06/14/2024
Course expires: 
06/30/2025

Faculty

Marguerite McDonald, MD (Chair)
Clinical Professor of Ophthalmology
New York University Langone Medical Center
New York, New York
Clinical Professor of Ophthalmology
Tulane University Health Sciences Center
New Orleans, Louisiana
Ophthalmic Consultants of Long Island
Oceanside, New York

 

Terry Kim, MD
Division Chief-Cornea, External Disease,
  and Refractive Surgery
Consulting Professor
Chief, Cornea and External Disease Service
Department of Ophthalmology
Duke University School of Medicine
Durham, North Carolina

Cathleen McCabe, MD
Medical Director
The Eye Associates
Bradenton, Florida

William Trattler, MD
Director of Cornea
Center for Excellence in Eye Care
Vice Chair of Research
Department of Ophthalmology
Herbert Wertheim College of Medicine
Florida International University
Miami, Florida

Disclosure Policy

MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.

Faculty

Terry Kim, MD, is a consultant for Alcon, Azura Ophthalmics, Bausch & Lomb Incorporated, Harrow, Inc, Kala Pharmaceuticals, Oyster Point Pharma, Inc, Santen Inc, Surface Pharmaceuticals Inc, Tarsus Pharmaceuticals, Inc, and Thea Pharmaceuticals Limited.

Cathleen McCabe, MD, is a consultant for AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Dompé US, Inc, Easee, EyePoint Pharmaceuticals, Eyevance, Imprimis Pharmaceuticals, Inc, iSTAR Medical, Ivantis Inc, LENSAR, LLC, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Omeros Corporation, Orasis Pharmaceuticals, Quidel Corporation, ScienceBased Health, Sight Sciences, SpyGlass Ophthalmics, Tarsus Pharmaceuticals, Inc, Visus Therapeutics, and Zeiss; is on the speakers bureau for AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Dompé US, Inc, EyePoint Pharmaceuticals, Ivantis Inc, LENSAR, LLC, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Omeros Corporation, and Sight Sciences; and is a contracted researcher for Alcon, Glaukos Corporation, Ivantis Inc, Ocular Therapeutix, Inc, Ora, Inc, Orasis Pharmaceuticals, and Sun Pharmaceutical Industries, Inc.

Marguerite McDonald, MD, is a consultant for AbbVie Inc, Alcon, Bausch & Lomb Incorporated, Johnson & Johnson Vision Care, Inc, OCULUS, Inc, Ocuphire Pharma, OCuSOFT Inc, Orca Surgical, Oyster Point Pharma, Inc, Sun Pharmaceutical Industries, Inc, and ThermaMEDx, LLC.

William Trattler, MD, is a consultant for AbbVie Inc, Alcon, Azura Ophthalmics, Bausch & Lomb Incorporated, BioTissue, BVI, CSI Dry Eye, Dompé US, Inc, Glaukos Corporation, Horizon Therapeutics plc, Johnson & Johnson Vision Care, Inc, LENSAR, LLC, Ocular Science, OCULUS Surgical, Inc, Sight Sciences, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, TissueTech, Inc, Trefoil Therapeutics, LLC, Verséa Health, Inc, Visiox Pharmaceuticals, Visus Therapeutics, and Zeiss; is on the speakers bureau for Bausch & Lomb Incorporated, BVI, Sun Pharmaceutical Industries, Inc, and TissueTech, Inc; and has individual stocks or stock options in Aperta Biosciences, LLC, CSI Dry Eye Software, Epion Health, Inc, RxSight, Tarsus Pharmaceuticals, Inc, and Trefoil Therapeutics, LLC.

Peer Reviewer

This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.

Planners, Managers, and Writers

Medical Writer: Cheryl Guttman has individual stocks or stock options in AbbVie Inc and Johnson & Johnson Vision Care, Inc.

Other MedEdicus planners and managers have no relevant commercial relationships to disclose.

Accreditation Statement

MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Commercial Support

This continuing medical education activity is supported through an educational grant from Bausch & Lomb Incorporated.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Provider Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

Disclaimer

The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or Bausch & Lomb Incorporated.

This CME activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 311

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 Participation
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CME information for this activity.